Small molecule inhibitors for treatment of a range of neurodegenerative diseases

FundaMental Pharma is pioneering a novel approach to combat neurodegeneration through the development of NMDAR/TRPM4 (N/T) Interface Inhibitors. These first-in-class inhibitors are designed to selectively target and abolish the neurotoxic effects associated with extrasynaptic NMDA receptors (NMDARs) while preserving the beneficial functions of synaptic NMDARs. This innovative mechanism aims to halt neurodegeneration, restore neuronal function, and maintain overall brain health, providing a promising therapeutic avenue for conditions such as Amyotrophic Lateral Sclerosis (ALS) and potentially other neurodegenerative diseases.

The company's research has uncovered the antagonistic signaling between synaptic and extrasynaptic NMDA receptors, leading to a deeper understanding of the molecular basis of their toxic actions. By focusing on the interaction between NMDARs and TRPM4, FundaMental Pharma is developing neuroprotectants that could prevent neuronal death caused by glutamate neurotoxicity. This approach not only targets ALS, a rapidly progressive and currently untreatable neurodegenerative disease, but also holds potential applications for other conditions like Huntington's Disease, Stroke, and Alzheimer's Disease, indicating a broad spectrum of therapeutic possibilities.

Germany

FundaMental Pharma - We are an early stage start-up company having laid the foundation for the development of a class of neuroprotective small molecules with an entirely new pharmacological mode of action. FMP neuroprotectiva are expected to be broadly applicable in the treatment of currently untreatable human neurological conditions. These include vascular brain damage and dementia, traumatic brain injury, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), Huntington’s disease (HD), retina degeneration, and brain damage caused by virus or parasite infections.

FundaMental Pharma

Company Details